Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Growth, Trends And Forecast 2023 To 2030

Report ID: IBI1566204 | Category: Service & Software | Pages: 145 | Format: PDF | Published Date: August 01,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3550.00 Multi User-$4550.00

Report Description
View Table of Contents

Report Summary

The Acute Myeloid Leukemia (AML) Therapeutics market report provides a detailed analysis of Spanish market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and Spanish market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The Spanish Acute Myeloid Leukemia (AML) Therapeutics market size is estimated to be worth US$ 559.6 million in 2022 and is forecast to a readjusted size of USD 1129.6 million by 2030 with a CAGR of 10.6% during review period. Hospital accounting for  % of the Acute Myeloid Leukemia (AML) Therapeutics Spanish market in 2022, is projected to value USD   million by 2030, growing at a  % CAGR in next six years. While Chemotherapy segment is altered to a  % CAGR between 2023 and 2030.
Spanish key companies of Acute Myeloid Leukemia (AML) Therapeutics include Bristol-Myers Squibb, Novartis, Roche, Genmab, and GlaxoSmithKline Pharmaceuticals, etc. In terms of revenue, the Spanish top four players hold a share over  % in 2022.
Market segmentation
Acute Myeloid Leukemia (AML) Therapeutics market is split by Type and by Application. For the period 2017-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
    Chemotherapy
    Radiation therapy
    Stem Cell Transplant
    Targeted Therapy
    Others
Market segment by Application, can be divided into
    Hospital
    Clinics
    Others
Market segment by players, this report covers
    Bristol-Myers Squibb
    Novartis
    Roche
    Genmab
    GlaxoSmithKline Pharmaceuticals
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Acute Myeloid Leukemia (AML) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Acute Myeloid Leukemia (AML) Therapeutics, with revenue, gross margin and Spanish market share of Acute Myeloid Leukemia (AML) Therapeutics from 2017 to 2023.
Chapter 3, the Acute Myeloid Leukemia (AML) Therapeutics competitive situation, revenue and Spanish market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2023.and Acute Myeloid Leukemia (AML) Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2030.
Chapter 11 and 12, to describe Acute Myeloid Leukemia (AML) Therapeutics research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Therapeutics
    1.2 Classification of Acute Myeloid Leukemia (AML) Therapeutics by Type
        1.2.1 Overview: Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type: 2017 Versus 2022 Versus 2030
        1.2.2 Spanish Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Type in 2022
        1.2.3 Chemotherapy
        1.2.4 Radiation therapy
        1.2.5 Stem Cell Transplant
        1.2.6 Targeted Therapy
        1.2.7 Others
    1.3 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market by Application
        1.3.1 Overview: Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application: 2017 Versus 2022 Versus 2030
        1.3.2 Hospital
        1.3.3 Clinics
        1.3.4 Others
    1.4 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size & Forecast
    1.5 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast by Region
        1.5.1 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region: 2017 VS 2022 VS 2030
        1.5.2 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region, (2017-2023)
        1.5.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size and Prospect (2017-2030)
        1.5.4 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size and Prospect (2017-2030)
        1.5.5 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size and Prospect (2017-2030)
        1.5.6 South America Acute Myeloid Leukemia (AML) Therapeutics Market Size and Prospect (2017-2030)
        1.5.7 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size and Prospect (2017-2030)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Acute Myeloid Leukemia (AML) Therapeutics Market Drivers
        1.6.2 Acute Myeloid Leukemia (AML) Therapeutics Market Restraints
        1.6.3 Acute Myeloid Leukemia (AML) Therapeutics Trends Analysis
2 Company Profiles
    2.1 Bristol-Myers Squibb
        2.1.1 Bristol-Myers Squibb Details
        2.1.2 Bristol-Myers Squibb Major Business
        2.1.3 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
        2.1.4 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, 2022, and 2023)
        2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.2 Novartis
        2.2.1 Novartis Details
        2.2.2 Novartis Major Business
        2.2.3 Novartis Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
        2.2.4 Novartis Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, 2022, and 2023)
        2.2.5 Novartis Recent Developments and Future Plans
    2.3 Roche
        2.3.1 Roche Details
        2.3.2 Roche Major Business
        2.3.3 Roche Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
        2.3.4 Roche Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, 2022, and 2023)
        2.3.5 Roche Recent Developments and Future Plans
    2.4 Genmab
        2.4.1 Genmab Details
        2.4.2 Genmab Major Business
        2.4.3 Genmab Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
        2.4.4 Genmab Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, 2022, and 2023)
        2.4.5 Genmab Recent Developments and Future Plans
    2.5 GlaxoSmithKline Pharmaceuticals
        2.5.1 GlaxoSmithKline Pharmaceuticals Details
        2.5.2 GlaxoSmithKline Pharmaceuticals Major Business
        2.5.3 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Product and Solutions
        2.5.4 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, 2022, and 2023)
        2.5.5 GlaxoSmithKline Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Spanish Acute Myeloid Leukemia (AML) Therapeutics Revenue and Share by Players (2019, 2020, 2021, 2022, and 2023)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Acute Myeloid Leukemia (AML) Therapeutics Players Market Share in 2022
        3.2.2 Top 10 Acute Myeloid Leukemia (AML) Therapeutics Players Market Share in 2022
        3.2.3 Market Competition Trend
    3.3 Acute Myeloid Leukemia (AML) Therapeutics Players Head Office, Products and Services Provided
    3.4 Acute Myeloid Leukemia (AML) Therapeutics Mergers & Acquisitions
    3.5 Acute Myeloid Leukemia (AML) Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Spanish Acute Myeloid Leukemia (AML) Therapeutics Revenue and Market Share by Type (2017-2023)
    4.2 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Forecast by Type (2023-2030)
5 Market Size Segment by Application
    5.1 Spanish Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Application (2017-2023)
    5.2 Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Forecast by Application (2023-2030)
6 North America by Country, by Type, and by Application
    6.1 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type (2017-2030)
    6.2 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2017-2030)
    6.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
        6.3.1 North America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Country (2017-2030)
        6.3.2 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        6.3.3 Canada Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        6.3.4 Mexico Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
7 Europe by Country, by Type, and by Application
    7.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type (2017-2030)
    7.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2017-2030)
    7.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
        7.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Revenue by Country (2017-2030)
        7.3.2 Germany Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        7.3.3 France Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        7.3.4 United Kingdom Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        7.3.5 Russia Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        7.3.6 Italy Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type (2017-2030)
    8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2017-2030)
    8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region
        8.3.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Revenue by Region (2017-2030)
        8.3.2 China Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        8.3.3 Japan Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        8.3.4 South Korea Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        8.3.5 India Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        8.3.6 Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        8.3.7 Australia Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
9 South America by Country, by Type, and by Application
    9.1 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type (2017-2030)
    9.2 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2017-2030)
    9.3 South America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
        9.3.1 South America Acute Myeloid Leukemia (AML) Therapeutics Revenue by Country (2017-2030)
        9.3.2 Brazil Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        9.3.3 Argentina Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue by Type (2017-2030)
    10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue by Application (2017-2030)
    10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country
        10.3.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Revenue by Country (2017-2030)
        10.3.2 Turkey Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        10.3.3 Saudi Arabia Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
        10.3.4 UAE Acute Myeloid Leukemia (AML) Therapeutics Market Size and Forecast (2017-2030)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Spanish Acute Myeloid Leukemia (AML) Therapeutics Market Growth, Trends And Forecast 2023 To 2030

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?